MediWound Reports Second Quarter 2017 Financial Results
YAVNE, Israel, Aug. 03, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and six months ended June 30, 2017.
Operational and Financial Highlights of second quarter 2017 and recent weeks include:
Total revenues for the second quarter of 2017 were $0.69 million, a 93% increase from $0.36 million in the second quarter of 2016, underscoring the continued growth of NexoBrid® sales
Operational and Financial Highlights of second quarter 2017 and recent weeks include:
Total revenues for the second quarter of 2017 were $0.69 million, a 93% increase from $0.36 million in the second quarter of 2016, underscoring the continued growth of NexoBrid® sales